
In billboard campaign, CT health system pressures insurer. What it means for patients.
You may have seen the deluge of billboards.
Farmington-based UConn Health is ramping up the pressure in its contract negotiations with ConnectiCare, taking out billboards at nearly a dozen prominent locations along highways in the Hartford area, urging the insurer to agree to higher reimbursement rates for services.
The billboards — along I-84 and I-91 — proclaim: 'UConn Health needs ConnectiCare to step up.'
'We're using ConnectiCare as a test case for what is coming down the line next,' Jennifer Walker, a UConn Health spokeswoman, said. 'Every other [insurer] is coming up after this. And it's going to go the same way. We letting them know that we are going to put the public pressure on it to stand up for ourselves.'
UConn Health argues its reimbursement rate is the lowest, behind all hospitals in Connecticut, despite revenue growth in the last decade and rankings that place it in the top tier of hospitals nationwide. At the same time, medical costs are rising, and Gov. Ned Lamont wants the health system — an arm of the University of Connecticut — to be more financially self-sufficient.
ConnectiCare's contract with UConn Health — the parent of John Dempsey Hospital, a network of clinics and more than 600 providers — expired on April 15. The two sides are now in a 60-day 'cooling off' period — ending June 14 —in which the two sides continue to negotiate.
On Thursday, UConn Health sent letters to ConnectiCare patients scheduled for appointments after June 14, who will either have their appointments canceled or go 'out-of-network', which can mean higher out-of-pocket costs than 'in-network.' Federal caps on out-of-pocket costs also may not apply to care that is out-of-network.
The contract negotiations cover ConnectiCare's commercial coverage, which includes employer-sponsored plans, and Medicare Advantage plans, which are sold by private insurers and offer Medicare coverage plus additional benefits. UConn Health has about 9,000 ConnectiCare patients that are affected, Walker said.
Consumers who find themselves out-of-network may be forced to find new health care providers that are in-network.
UConn Health said there can be exceptions for 'continuing care' such as chemotherapy treatments that remain in-network even in the absence of a contract. UConn Health also said it has tried to reschedule some appointments so they fall before the June 14 deadline, Walker said.
ConnectiCare, headquartered in Farmington, was acquired by California-based Molina Healthcare on Feb. 4. ConnectiCare did not respond to an email seeking comment.
UConn Health also oversees the university's medical and dental schools, plus its medical research. In the current fiscal year, UConn Health received about $193 million in state funding, or 12.5% of its total budget, UConn Health officials have said.
A six-month study last year of UConn Health's operations by a high-profile health care consulting firm found that UConn needed to generate more money from patient care in order to compete in the health care world of the future.
'We have the governor saying you can't depend on us anymore, you have to make your own money,' Walker said. 'And this is a way to close the gap on this, and not putting the burden n the taxpayers of Connecticut, making sure we are being paid as fairly as everyone else.'
Reporting by Courant Staff Writer Christopher Keating is included.
Kenneth R. Gosselin can be reached at kgosselin@courant.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.


New York Times
an hour ago
- New York Times
Why This Father-Daughter Wedding Tradition Endures
On her wedding day, Vieneese Stanton didn't glide through the sanctuary of a stately church or down a flower-lined aisle. She stood at the end of a hospital hallway in the cancer wing of the UCSF Medical Center in San Francisco, beaming in a gauzy white gown, ready to surprise her terminally ill father with the chance to walk her down the aisle to her groom. In February 2017, Ms. Stanton's father, Preston Rolan, was diagnosed with an aggressive cancer that overproduces abnormal white cells in the bone marrow. Ms. Stanton, 35, who lives in Richmond, Calif., had hoped he would attend her wedding the following April, but then a deadly infection metastasized in Mr. Rolan's lung. 'We didn't know if he'd make it,' said Ms. Stanton, an administrator at San Domenico School in San Anselmo, Calif. 'But I couldn't imagine that day without him.' The couple moved their wedding to a city hall ceremony in November 2018, with a quick hospital visit planned so Mr. Rolan could see his daughter in her gown. But the hospital staff had bigger plans. They transformed Mr. Rolan's daily stroll around the hospital into a surprise walk down the aisle. On Nov. 16, 2018, when Mr. Rolan turned the corner during his walk, 'I was standing there in my dress. He was like, 'Oh my God, what's going on?!'' Ms. Stanton recalls. 'He thought I was headed to Vegas or something. He had no clue we were doing it right there.' That touching walk together, which Ms. Stanton said lasted less than a minute, was one that she will cherish. 'I'm just grateful I could have that moment with him. He passed away just three weeks later, but he got to see the wedding,' Ms. Stanton said. 'He was so happy.' Want all of The Times? Subscribe.


Axios
4 hours ago
- Axios
Exclusive: Autonomize AI gets $28M for health agents
Autonomize AI, a provider of AI agents to health systems and plans, raised $28 million in Series A funding, CEO Ganesh Padmanabhan tells Axios exclusively. The big picture: It's the latest sign of investor appetite for infrastructure-layer AI in health care — especially platforms that promise scale, compliance, and a clear ROI. Follow the money: Autonomize plans to expand deployment of its "Copilot" AI agents across payers, providers, and life sciences organizations. Valtruis, Cigna Ventures, and Tau Ventures led the round, joined by previous investors Asset Management Ventures, ATX Venture Partners, and Capital Factory. The Series A provides 24-month runway, though the company could raise before then, Padmanabhan says. How it works: Austin-based Autonomize's agentic AI platform stitches together pre-trained agents for tasks like benefits verification, care planning, and chart review. The company uses a human-in-the-loop model and offers explainability and compliance features — two key factors for success in health care. Most of its customers are payors, followed by value-based care providers and syndicated health plans. Between the lines: Autonomize was built specifically for the highly regulated business of health care, per Padmanabhan. "I've met nurses who have a 400-page binder on their desk that they still refer to before making adjudication decisions within health plans," says Padmanabhan. "There's no way an AI agent is going to find that because that data, that knowledge, is not digitized." What they're saying: "The way the technology is configured is, you set up an agent for a particular use case and it's reusable for others," says Valtruis managing director Mike Spadafore. "A lot of these workflows are made up of 15, 20 different steps that you assemble into different workflows," Spadafore adds, noting Autonomize's repeatability was attractive. "A complex workflow, like care management or like prior authorization, is actually multiple sub workflows," Padmanabhan says. A benefit check is one example —where users are looking at patient information across multiple documents. Reality check: The market is flooded with "AI for health care" startups, but most are still struggling to show meaningful, repeatable results.